NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer cells that help to suppress tumors, but also are involved in the generation and maintenance of adaptive immune responses.  The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of innate immune cells which provide antitumor …Read More >

Join WuXi AppTec at IMMUNOLOGY2024™. For this year’s annual meeting of the American Association of Immunologists (AAI), WuXi Biology has been selected to present five noteworthy posters, showcasing our panel of preclinical models representing urticaria, nephritis, rheumatoid arthritis, gout, and atopic dermatitis. Stop by Booth 777 to get your questions answered by one of our …Read More >

OncoWuXi Express| Immunology 2024™ Poster Sneak Peek Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the highlights of posters we will present at …Read More >

A new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum.  As the discovery pipeline widens and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver cell-killing radioisotopes. One area that is showing considerable promise is the incorporation of an isotope-chelating moiety …Read More >

Rat tumor models are a better mimic of human pathology compared to mice. The tumor stroma component of rats is about 1.5 to 2-fold higher relative to mice. Rats are considered an ideal model for preclinical efficacy studies, as they are physiologically, metabolically, and genetically more similar to humans.  To support drug discovery teams, WuXi …Read More >

PD-1 blockade has demonstrated remarkable clinical efficacy across various tumor types. However, primary or acquired resistance eventually leads to cancer progression in clinical settings. Understanding the underlying mechanisms of resistance is both necessary and urgent to enhance clinical outcomes. At AACR 2024, WuXi AppTec presented a poster describing the development of two types of anti-PD-1 …Read More >

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated through CAR-T, leading to the inhibition of CAR-T cell activity via the PD-1 pathway.  At AACR 2024, WuXi AppTec presented a poster describing an engineered CAR-T therapy that targets mesothelin and concurrently expresses a membrane-bound …Read More >

WuXi AppTec scientists published a study in the open access archive ChemRxiv describing the discovery of highly selective, novel, heme oxygenase-1 (HO-1) targeting molecules. HO-1, primarily a heme-degrading enzyme, has been identified as a potential therapeutic target in diseases such as cancer and neurodegenerative disorders. Here, we report the discovery of five series of novel …Read More >

Despite the success of delivery technologies such as lipid nanoparticles and trivalent GalNAc conjugation, targeted delivery of oligonucleotides to extra hepatic tissues remains a challenge.  At this year’s OPT Congress, WuXi AppTec presented a poster showing the utilization of our peptide-based DNA-encoded library screening platform to identify endocytosis receptor-binding peptides.  The binding affinity of hit …Read More >